查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751189

北美外用药物 CDMO 市场规模、份额、趋势分析报告：按产品、服务、最终用途、国家、细分市场预测，2025 年至 2030 年

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Product (Semi-solid, Liquid), By Service (Contract Development, Contract Manufacturing), By End Use, By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

北美外用药物 CDMO 市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，北美外用药物CDMO市场规模预计到2030年将达到272.2亿美元，2025年至2030年的复合年增长率为10.88%。

研发投入的不断增加，以及对多种皮肤病新型治疗药物的需求不断增长，推动了外用药物CDMO市场的需求不断增长。由于使用方便、副作用小，消费者对多种外用溶液的偏好日益增长，也是市场成长的驱动因素。

对创新和新产品开发日益增长的需求预计将改善市场需求，而竞争压力和价格担忧正促使企业将开发新药和生产外包。预计这将推动整体市场成长。此外，CDMO正在利用奈米技术等先进技术在分子层面上操纵药物颗粒，以提高药物稳定性和生物有效性。此外，微胶囊技术透过保护精细成分并实现控制释放和标靶药物传递来提高治疗效果。这些技术进步正在加速北美市场的成长潜力。

该CDMO积极与製药公司合作，并就创新药物开发和多种外用药物製剂的生产达成长期协议。例如，2023年1月，专注于皮肤外用药物的知名供应商－瑞士-美国CDMO与EveryDrop分配平台的发明者LiquiGlide达成合作。透过此次合作，该公司将利用LiquiGlide创新、无毒、光滑的表面技术，消除液体和固体之间的摩擦，从而减少消费包装产品中的产品废弃物。

北美外用药物CDMO市场报告重点：

  • 根据产品类型，半固态剂型预计将在 2024 年占据市场主导地位，收入份额超过 66.47%。这是由于其具有许多优势，例如易于给药，以及由于多种副作用，患者更喜欢外用药物而不是口服药物，这预计将推动对该领域的需求。
  • 根据服务类型，契约製造部门预计在预测期内将以显着的复合年增长率成长。
  • 按赞助商划分，製药公司将在 2024 年占据最大的市场占有率。製药公司对开发和商业化创新外用药物的研发投资的发展预计将推动市场收益的成长。
  • 由于该地区市场参与企业强大、政府对优质医疗保健的支持以及对化妆品的高需求，美国在北美外用 CDMO 行业中占据主导地位。

目录

第一章调查方法与范围

第二章执行摘要

3. 北美外用药物 CDMO 市场变数、趋势与范围

  • 市场展望
    • 母市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 定价分析
  • 外用药物CDMO产能展望
    • CDMO生产货柜容量
    • 外用药容器容量（产品类型）
  • 北美外用药物CDMO市场展望（依产品类型）
    • 2024 年北美外用药物 CDMO市场占有率（依产品类型划分）(%)
    • 处方药
    • 学名药
    • 非处方药
  • 北美外用药物CDMO市场分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19影响分析
    • 美国关税影响分析

第四章北美外用药物CDMO市场：产品预估与趋势分析

  • 2024年及2030年的产品市场占有率
  • 细分仪表板
  • 北美外用药物CDMO市场：产品展望
  • 2018年至2030年市场规模、预测及趋势分析
    • 半固态製剂
    • 液体製剂
    • 固态製剂
    • 经皮产品

第五章北美外用药物CDMO市场：服务估算与趋势分析

  • 2024年及2030年服务市场占有率
  • 细分仪表板
  • 北美外用药物 CDMO 市场：服务展望
  • 2018年至2030年市场规模、预测及趋势分析
    • 合约开发
    • 契约製造

6. 北美外用药物CDMO市场：最终用途预估及趋势分析

  • 2024 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 北美外用药物 CDMO 市场：依最终用途展望
  • 2018年至2030年市场规模、预测及趋势分析
    • 製药公司
    • 生物製药公司
    • 其他的

第七章 北美外用药物 CDMO 市场：各国估值及趋势分析

  • 2024 年及 2030 年各国市场
  • 各国市场仪表板
  • 各国市场
  • 2018-2030年市场规模、预测与趋势分析
  • 美国
    • 主要国家趋势
    • 竞争场景
    • 法律规范
  • 加拿大
    • 主要国家趋势
    • 竞争场景
    • 法律规范
  • 墨西哥
    • 主要国家趋势
    • 竞争场景
    • 法律规范

第八章 竞争态势

  • 公司/竞争对手分类
    • 市场领导者
    • 新兴企业
  • 2024 年公司市场占有率/估值分析
  • 公司简介
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre SA
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD.
    • MedPharm Ltd.
    • Zenvisionpharma
Product Code: GVR-4-68040-188-4

North America Topical Drugs CDMO Market Growth & Trends:

The North America topical drugs CDMO market size is anticipated to reach USD 27.22 billion by 2030, registering a CAGR of 10.88% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.

The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.

CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide's innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.

North America Topical Drugs CDMO Market Report Highlights:

  • Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 66.47% share in 2024, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
  • Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
  • Based on sponsors, the pharmaceutical companies segment held the largest market share in 2024. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
  • The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Parent Market Analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological advancements & growing R&D investments
      • 3.2.1.2. Rising demand for topical medications
      • 3.2.1.3. Expansion of manufacturing capacities and partnerships
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits the adoption of topical products
  • 3.3. Pricing Analysis
  • 3.4. Topical Drugs CDMO Capacity Outlook
    • 3.4.1. CDMO Manufacturing Container Capacity
    • 3.4.2. Topical Drugs Container Capacity By Product Type
  • 3.5. North America Topical Drugs CDMO Market Outlook By Product Category
    • 3.5.1. North America Topical Drugs CDMO Market Share, By Product Category, 2024 (%)
    • 3.5.2. Prescription Drugs
      • 3.5.2.1. Segment Overview
      • 3.5.2.2. Major Prescription Drugs, By Product Type
    • 3.5.3. Generic Drugs
      • 3.5.3.1. Segment Overview
      • 3.5.3.2. Major Generic Drugs, By Product Type
    • 3.5.4. Over-the-counter (OTC) Drugs
      • 3.5.4.1. Segment Overview
      • 3.5.4.2. Major OTC Drugs, By Product Type
  • 3.6. North America Topical Drugs CDMO Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis
    • 3.6.4. U.S. Tariff Impact Analysis

Chapter 4. North America Topical Drugs CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. North America Topical Drugs CDMO Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Semi-solid Formulations
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Creams
        • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ointments
        • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lotions
        • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
        • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Liquid Formulations
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Suspensions
        • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Solutions
        • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Solid Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Transdermal Products
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America Topical Drugs CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Service Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. North America Topical Drugs CDMO Market by Service Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Contract Development
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Formulation Development
        • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Analytical Testing
        • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Stability Testing
        • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
        • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Contract Manufacturing
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Clinical
        • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Commercial
        • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America Topical Drugs CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. North America Topical Drugs CDMO Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Pharmaceutical Companies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Biopharmaceutical Companies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. North America Topical Drugs CDMO Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2024 & 2030
  • 7.2. Country Market Dashboard
  • 7.3. Country Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Competitive scenario
    • 7.5.3. Regulatory framework
    • 7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Canada
    • 7.6.1. Key country dynamics
    • 7.6.2. Competitive scenario
    • 7.6.3. Regulatory framework
    • 7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Mexico
    • 7.7.1. Key country dynamics
    • 7.7.2. Competitive scenario
    • 7.7.3. Regulatory framework
    • 7.7.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. The Lubrizol Corporation
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product/service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Cambrex Corporation
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product/service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Contract Pharmaceuticals Limited
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product/service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Bora Pharmaceutical CDMO
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product/service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Ascendia Pharmaceuticals
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product/service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Pierre Fabre S.A.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product/service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Piramal Pharma Solutions
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product/service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DPT Laboratories, LTD.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product/service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. MedPharm Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product/service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Zenvisionpharma
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product/service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global topical drugs CDMO: market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Table 4 Global topical drugs: market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Table 5 Development stages baseline model parameter estimates, By topical drugs
  • Table 6 Global topical drugs CDMO manufacturing container capacity/batch
  • Table 7 Global topical drugs capacity, by product type (per unit)
  • Table 8 Global topical drugs capacity, by container type (per unit)
  • Table 9 North America topical drugs CDMO market share, by product category, 2024 (%)
  • Table 10 List of major prescription drugs, by product type (2024)
  • Table 11 List of major generic drugs, by product type (2024)
  • Table 12 List of major OTC drugs, by product type (2024)
  • Table 13 North America topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 14 North America topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 15 North America topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 16 North America topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 17 North America topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 18 North America topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 19 North America topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 20 North America topical drugs CDMO market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 21 U.S. topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 22 U.S. topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 23 U.S. topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 24 U.S. topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 25 U.S. topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 26 U.S. topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 27 U.S. topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 28 Canada topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 29 Canada topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 30 Canada topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 31 Canada topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 32 Canada topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 33 Canada topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 34 Canada topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 35 Mexico topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 36 Mexico topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 37 Mexico topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 38 Mexico topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 39 Mexico topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 40 Mexico topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 41 Mexico topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 42 Company profiles: Company overview
  • Table 43 Company profiles: Financial performance
  • Table 44 Company profiles: Service benchmarking
  • Table 45 Key company initiating service launches/upgrades
  • Table 46 Key companies initiating mergers/acquisitions/joint ventures
  • Table 47 Key companies initiating partnerships
  • Table 48 Key companies initiating expansion
  • Table 49 Key companies initiating others

List of Figures

  • Fig. 1 North America topical drugs CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
  • Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
  • Fig. 14 North America topical drugs CDMO market dynamics
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
  • Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
  • Fig. 19 Semi-solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Creams market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Lotions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Liquid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Suspensions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Transdermal products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
  • Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
  • Fig. 31 Contract development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Formulation development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Analytical testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Stability testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
  • Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
  • Fig. 41 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
  • Fig. 45 Regional outlook, 2023 & 2030
  • Fig. 46 Regional Market Share Analysis, 2023 & 2030
  • Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Market participant categorization
  • Fig. 54 Heat map analysis